Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edwards LifesciencesXSWX:EW +0.60%98 Forward Rate of Return (Yacktman) % is 3.91% as of Jun. 2026, which is 67% below its 10-year median of 12.02. GuruFocus rates XSWX:EW with a GF Score™ of 98/100 and a GF Value™ of CHF75.68. The stock has 5 warning signs investors should review. Among 377 Medical Devices & Instruments companies, Edwards Lifesciences ranks worse than 59.68% on this metric.
Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Edwards Lifesciences's forward rate of return for was 3.91%.
The historical rank and industry rank for Edwards Lifesciences's Forward Rate of Return (Yacktman) % or its related term are showing as below:
XSWX:EW'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.37 Med: 12.02 Max: 22.57
Current: 3.92
During the past 13 years, Edwards Lifesciences's highest Forward Rate of Return was 22.57. The lowest was 1.37. And the median was 12.02.
XSWX:EW's Forward Rate of Return (Yacktman) % is ranked worse than 59.68% of 377
companies
in the Medical Devices & Instruments industry
Industry Median: 8.23
vs XSWX:EW: 3.92
Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Edwards Lifesciences (XSWX:EW) Forward Rate of Return (Yacktman) % Explanation
Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.
Be Aware
In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.
Edwards Lifesciences Forward Rate of Return (Yacktman) % Related Terms
Edwards Lifesciences Forward Rate of Return (Yacktman) % Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's Forward Rate of Return (Yacktman) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences Forward Rate of Return (Yacktman) % Chart
XSWX:EW vs BSX, DXCM, GEHC: Forward Rate of Return (Yacktman) % Comparison
For the Medical Devices subindustry, Edwards Lifesciences's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences Forward Rate of Return (Yacktman) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Forward Rate of Return (Yacktman) % distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's Forward Rate of Return (Yacktman) % falls into.
Edwards Lifesciences Forward Rate of Return (Yacktman) % Calculation
Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Rate of Return (Yacktman) % of 3.91% mean?
Edwards Lifesciences (XSWX:EW) has a Forward Rate of Return (Yacktman) % of 3.91% as of Jun. 2026. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Edwards Lifesciences and its competitors. This is 67% below median its historical median of 12.02. Over the past decade, Edwards Lifesciences' Forward Rate of Return (Yacktman) % has ranged from 1.37 to 22.57. According to the industry distribution chart, Edwards Lifesciences ranks #225 out of 377 companies in the Medical Devices & Instruments industry, placing it in the top 59.7%.
Is Edwards Lifesciences' Forward Rate of Return (Yacktman) % too high?
Edwards Lifesciences' current Forward Rate of Return (Yacktman) % of 3.91% is 67% below median its 10-year median of 12.02. Over the past 10 years, this metric has ranged from a low of 1.37 to a high of 22.57. The Medical Devices & Instruments industry median Forward Rate of Return (Yacktman) % is 8.23. Edwards Lifesciences' value of 3.91% is 52.5% below this industry median. Based on the distribution chart, Edwards Lifesciences ranks #225 out of 377 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Edwards Lifesciences has a GF Score™ of 98/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Forward Rate of Return (Yacktman) % compare to BSX and DXCM?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #225 out of 377 companies for Forward Rate of Return (Yacktman) %. This places Edwards Lifesciences in the lower half of its industry. The industry median Forward Rate of Return (Yacktman) % is 8.23. Edwards Lifesciences' value of 3.91% is 52.5% below this benchmark. Historically, Edwards Lifesciences' own Forward Rate of Return (Yacktman) % has ranged from 1.37 to 22.57 over the past decade. While the company's 10-year median is 12.02 vs. the industry median of 8.23, Edwards Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Medical Devices & Instruments company?
The median Forward Rate of Return (Yacktman) % among Medical Devices & Instruments companies is 8.23, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current Forward Rate of Return (Yacktman) % of 3.91% is 52.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Forward Rate of Return (Yacktman) % is 8.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current Forward Rate of Return (Yacktman) % is 3.91%, which is 67% below median its own 10-year median of 12.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current Forward Rate of Return (Yacktman) % of 3.91%. The stock's GF Value™ is CHF75.68, compared to a current price of CHF72.07 — trading 4.8% below its estimated fair value. The current Forward Rate of Return (Yacktman) % is 3.91%, which is 67% below median its 10-year median of 12.02 and 52.5% below the Medical Devices & Instruments industry median of 8.23. Edwards Lifesciences' overall GF Score™ is 98/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current Forward Rate of Return (Yacktman) % is 3.91% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of CHF72.07 is trading 4.8% below its estimated GF Value™ of CHF75.68.
Key valuation signals for XSWX:EW:
Forward Rate of Return (Yacktman) %: 3.91% (67% below median its 10-year median of 12.02)
GF Value™: CHF75.68 vs. price of CHF72.07 (4.8% below fair value)
Industry Position: 52.5% below the Medical Devices & Instruments median (#225 of 377)
No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
98GF Score
Get the complete analysis for XSWX:EW
Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EW has been successfully added to your 
